

National Board of Examinations

Question Paper Name :	DNB Pharmacology Paper4
Subject Name :	DNB Pharmacology Paper4
Creation Date :	2022-06-25 18:45:16
Duration :	180
Share Answer Key With Delivery Engine :	No
Actual Answer Key :	No

DNB Pharmacology Paper4

Group Number :	1
Group Id :	3271871164
Group Maximum Duration :	0
Group Minimum Duration :	180
Show Attended Group? :	No
Edit Attended Group? :	No
Break time :	0
Group Marks :	100
Is this Group for Examiner? :	No
Examiner permission :	Cant View
Show Progress Bar? :	No

DNB Pharmacology Paper4

Section Id :	3271871167
Section Number :	1

Section type :	Offline
Mandatory or Optional :	Mandatory
Number of Questions to be attempted :	10
Section Marks :	100
Enable Mark as Answered Mark for Review and Clear Response :	Yes
Maximum Instruction Time :	0
Sub-Section Number :	1
Sub-Section Id :	3271871171
Question Shuffling Allowed :	No

Question Number : 1 Question Id : 32718710692 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Please write your answers in the answer booklet within the allotted pages as follows:-

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

1. Classify medical devices and regulations of medical devices in India. [5+5]

Question Number : 2 Question Id : 32718710693 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Discuss novel drug targets for human immunodeficiency virus. [10]

Question Number : 3 Question Id : 32718710694 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

What is Signal? Discuss the role of Signal Review Committee in Pharmacovigilance programme of

India (PvPI). [2+8]

Question Number : 4 Question Id : 32718710695 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Discuss the recent advances in antimicrobial agents targeting gram-negative organisms. [10]

Question Number : 5 Question Id : 32718710696 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Write about adaptive designs in clinical trials. [10]

Question Number : 6 Question Id : 32718710697 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Describe recent advances for the management of Covid-19. [10]

Question Number : 7 Question Id : 32718710698 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Discuss the roles and composition of Institutional Ethics Committee as per ICMR guideline and NDCT Rule, 2019. [10]

Question Number : 8 Question Id : 32718710699 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Discuss the therapeutic potential and current status of cannabinoids. [10]

Question Number : 9 Question Id : 32718710700 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

a) Role of placebo in clinical trials. [5]

b) Informed consent. [5]

Question Number : 10 Question Id : 32718710701 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Explain about nano-vaccine and its advantages & limitations. [10]